Want to see OPCH full AI Analyst Report?
OPCH Stock Chart & Stats
$21.66
$0.58(2.75%)
At close: 4:00 PM EDT
$21.66
$0.58(2.75%)
Day’s Range― - ―
52-Week Range$18.01 - $36.80
Previous CloseN/A
Volume1.57M
Average Volume (3M)2.33M
Market Cap
$3.45B
Enterprise Value$4.29K
Total Cash (Recent Filing)$193.77M
Total Debt (Recent Filing)$1.27B
Price to Earnings (P/E)17.3
Beta0.45
Next Earnings
Oct 29, 2026EPS Estimate
0.49Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.33
Shares Outstanding149,785,250
10 Day Avg. Volume1,961,194
30 Day Avg. Volume2,330,089
Financial Highlights & Ratios
PEG Ratio6.12
Price to Book (P/B)3.89
Price to Sales (P/S)0.91
P/FCF Ratio23.78
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$27.50Price Target Upside26.96% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering9
EPS Forecast (FY)1.87
Revenue Forecast (FY)$5.75B
Bulls Say, Bears Say
Bulls Say
Cash GenerationConsistently positive operating cash flow and very high FCF conversion (TTM ~93% of net income; Q2 OCF $184M) underpin durable ability to fund operations, invest in clinics/tech, pay down/ service debt and execute buybacks without relying on external financing.
Top-line Momentum & Portfolio BreadthStrong historical TTM revenue expansion and recent sequential growth reflect successful therapy adoption and volume recovery. Diverse portfolios (acute, IG neuro, rare/orphan) reduce single-product dependency and support sustainable volume-driven revenue growth over the coming quarters.
National Network & Site MixA broad ambulatory/home infusion footprint and recent clinic additions deepen payer relationships and referral capture, aligning with secular shifts toward lower-cost alternate-site care. Scale in sites and nursing suites supports cost efficiency and durable competitive positioning.
Bears Say
CID Portfolio HeadwindsChronic inflammatory (CID) product weakness is a material mix and volume drag expected to reduce revenue and gross profit (~600bps revenue, ~$55M GP). This structural portfolio gap can persist and compress margins and growth until coverage or product mix normalizes.
Margin CompressionNotable decline in net margin over recent periods signals mix and pricing pressure. Lower margins reduce internal funding for growth, increase sensitivity to reimbursement shifts, and make sustained EPS and cash targets harder to achieve absent margin recovery or cost gains.
Balance Sheet / Leverage ClarityManagement reports manageable but material leverage (net debt ~2.1x at Q2) and a TTM data inconsistency that obscures the latest debt picture. Moderate leverage limits strategic flexibility and raises risk if cash generation weakens or if execution falters.
OPCH FAQ
What was Option Care Health Inc’s price range in the past 12 months?
Option Care Health Inc lowest stock price was $18.01 and its highest was $36.80 in the past 12 months.
What is Option Care Health Inc’s market cap?
Option Care Health Inc’s market cap is $3.45B.
When is Option Care Health Inc’s upcoming earnings report date?
Option Care Health Inc’s upcoming earnings report date is Oct 29, 2026 which is in 83 days.
How were Option Care Health Inc’s earnings last quarter?
Option Care Health Inc released its earnings results on Jul 29, 2026. The company reported $0.45 earnings per share for the quarter, beating the consensus estimate of $0.426 by $0.024.
Is Option Care Health Inc overvalued?
According to Wall Street analysts Option Care Health Inc’s price is currently Undervalued.
Does Option Care Health Inc pay dividends?
Option Care Health Inc does not currently pay dividends.
What is Option Care Health Inc’s EPS estimate?
Option Care Health Inc’s EPS estimate is 0.49.
How many shares outstanding does Option Care Health Inc have?
Option Care Health Inc has 149,785,250 shares outstanding.
What happened to Option Care Health Inc’s price movement after its last earnings report?
Option Care Health Inc reported an EPS of $0.45 in its last earnings report, beating expectations of $0.426. Following the earnings report the stock price went up 6.45%.
Which hedge fund is a major shareholder of Option Care Health Inc?
Currently, no hedge funds are holding shares in OPCH
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Option Care Health Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$27.50 (26.96% Upside)
$27.50 (26.96% Upside)
Blogger Sentiment
Neutral
OPCH Sentiment 50%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 50.1K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $1.9M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▲ 0.2%
Last 30 Days ▼ 4.0%
Last 30 Days ▼ 4.0%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-26.54%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-0.12%
Trailing 12-Months
Company Description
Option Care Health Inc
Option Care Health, Inc. delivers infusion services to patients in their homes and other non-hospital settings throughout the United States. The company offers a broad spectrum of specialized infusion treatments, including therapies for various infections, management of heart failure, and comprehensive nutritional support (both intravenous and tube feeding) for individuals with acute or chronic conditions such as stroke, cancer, and digestive illnesses. They also provide immunoglobulin infusions for immune system deficiencies and treatments targeting chronic inflammatory disorders like Crohn's disease, plaque psoriasis, psoriatic arthritis, rheumatoid arthritis, and ulcerative colitis. Furthermore, Option Care Health assists in managing the progression of neurological conditions such as amyotrophic lateral sclerosis (ALS) and Duchenne muscular dystrophy. They also administer infusion therapies for bleeding disorders and provide crucial support for women experiencing high-risk pregnancies. Other specialized infusion services encompass pain relief, chemotherapy, and respiratory care. Complementing these medical offerings, the company provides professional nursing services. Option Care Health, Inc. maintains its primary corporate office in Bannockburn, Illinois.
OPCH Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call presented a balance of meaningful operational and financial positives — including sequential revenue and EBITDA growth, strong cash generation ($184M in Q2), active share repurchases ($150M), clinic expansion, and progress in key portfolios (acute, IG neuro, rare/orphan) — while acknowledging persistent headwinds tied to the CID portfolio that are expected to depress 2026 revenue (~600 bps) and gross profit (~$55M). Management emphasized execution of commercial, technology and cost initiatives to drive sequential improvement through the back half of the year, but several initiatives and new therapy launches carry timing and execution risk.View all OPCH earnings summariesOPCH Stock 12 Month Forecast
Average Price Target
$27.50
▲(26.96% Upside)
Technical Analysis
Addus Homecare
―
Chemed
―
National Healthcare
―
Surgery Partners
―
Aveanna Healthcare Holdings
―
Ownership Overview
1.36% Insiders
38.75% Mutual Funds
6.80% Other Institutional Investors
21.97% Public Companies and
Individual Investors










